Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Bayer
Aktis Oncology, Inc.
EMD Serono
Seagen Inc.
Boehringer Ingelheim
Seagen Inc.
Compass Therapeutics
Eli Lilly and Company
Compass Therapeutics
National Cancer Institute (NCI)
Bristol-Myers Squibb
Novartis
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genentech, Inc.
AstraZeneca
Boehringer Ingelheim
Fox Chase Cancer Center
Radboud University Medical Center
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim
National Cancer Institute (NCI)
Providence Health & Services
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Eli Lilly and Company
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Royal Marsden NHS Foundation Trust
The Methodist Hospital Research Institute
OncoC4, Inc.
City of Hope Medical Center
Exscientia AI Limited
USWM, LLC (dba US WorldMeds)
Seagen Inc.
KaliVir Immunotherapeutics
Pfizer
Pfizer
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
AstraZeneca
Zumutor Biologics Inc.
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Arcus Biosciences, Inc.